CJC-1295 / Ipamorelin
CJC-IPA · 5 + 5 mg · nightly, no-DAC
SCIENCE • STRENGTH • LONGEVITY
Before you draw anything. Every figure in this document assumes a 5 mg + 5 mg co-lyophilized blend vial reconstituted with 2.5 mL of bacteriostatic water. Confirm both the blend ratio and the milligram strengths printed on your vial first — 10 mg + 10 mg vials also exist and every number here would double.
This is a two-compound blend working on two different receptors. CJC-1295 without DAC is a GHRH analog that signals the pituitary the same way tesamorelin does. Ipamorelin is a ghrelin-receptor agonist that triggers a separate growth hormone pulse. Pairing a GHRH analog with a GHRP is the most common structure in growth hormone research because the two pathways compound rather than overlap.
No-DAC changes the schedule, not just the molecule. CJC-1295 without DAC has a half-life around 30 minutes, so it is dosed daily to align with natural growth hormone pulses. The DAC-modified version lasts 6 to 8 days and is dosed weekly. Running a no-DAC product on a with-DAC schedule delivers almost no signal. Confirm which variant you have.
RECONSTITUTION
| Parameter | Value |
|---|---|
| Vial | 5 mg CJC-1295 (no DAC) + 5 mg ipamorelin, 1:1 by weight |
| Bacteriostatic water | 2.5 mL |
| Concentration | 2 mg/mL of each peptide (4 mg/mL total blend) |
| Conversion | 5 units = 100 mcg of each · 1 unit = 20 mcg of each |
| Route | Subcutaneous |
| Timing | Bedtime, at least 2 hours after the last meal |
| Reconstituted storage | 2–8 °C, up to 28 days. Avoid freeze-thaw. |
| Lyophilized storage | −20 °C, 12+ months |
Because the blend is co-lyophilized at a fixed 1:1 ratio, both peptides dissolve in one step and the concentration applies to each compound independently — not to a combined total. Adding more water lowers both concentrations proportionally and never changes the ratio between them.
- Let the vial and the bacteriostatic water reach room temperature.
- Swab both stoppers with alcohol and let them dry.
- Draw the planned volume of bacteriostatic water into a sterile syringe.
- Aim the stream at the inside wall of the glass, never directly at the powder.
- Roll gently for 30 to 60 seconds until fully dissolved. Never shake — shaking damages the peptide.
- Confirm the solution is clear before use.
- Label with product, concentration, and date, then refrigerate.
DOSING SCHEDULE
| Phase | Amount (each peptide) | Units | Frequency | Duration |
|---|---|---|---|---|
| Starting | 100 mcg | 5 | Nightly, 5 on / 2 off | Weeks 1–2 |
| Standard | 200 mcg | 10 | Nightly, 5 on / 2 off | Weeks 3–4 |
| Upper | 300 mcg | 15 | Nightly, 5 on / 2 off | Week 5 onward if tolerated |
Amounts refer to each peptide, not the combined total — a 10-unit draw delivers 200 mcg of CJC-1295 and 200 mcg of ipamorelin. Hold each step for at least a week before advancing.
Timing is doing real work here. Growth hormone releases in pulses, and the largest natural pulse occurs shortly after sleep onset. Dosing at bedtime on an empty stomach stacks the injected signal onto that pulse. Food — carbohydrate and fat in particular — blunts the response, which is why the two-hour fasting gap is part of the protocol rather than a suggestion.
Cycling and coverage
- Run 8 to 12 weeks, then take a 4-week break. Receptor sensitivity declines with uninterrupted stimulation, and the break is what restores it.
- At 200 mcg each per night, 5 nights weekly, one 5 mg + 5 mg vial covers roughly 5 weeks.
- The 28-day reconstituted window is the practical constraint. Plan the reconstitution volume around what gets used inside four weeks.
- Rotate sites across abdomen, thigh, and upper arm.
CAUTIONS
- Active malignancy. Growth hormone and IGF-1 elevation are contraindicated where a proliferative process is present.
- Diabetes or impaired glucose tolerance — GH elevation reduces insulin sensitivity.
- Do not run alongside tesamorelin. Both CJC-1295 and tesamorelin are GHRH analogs acting on the same receptor, so combining them doubles one signal rather than adding a second.
- Never combine with exogenous growth hormone.
- Pregnancy or breastfeeding.
- Both compounds are prohibited by WADA and will test positive.
Monitoring
IGF-1 at baseline and after the first cycle is the reading that reflects response. Watch for water retention, joint aching, and tingling in the hands — these are the standard signals of an amount that has gone too high, and they resolve on stepping back down.
Supplies
- U-100 insulin syringes, 0.3 mL / 30-unit. Half-unit gradations matter at these draw volumes.
- Bacteriostatic water, 10 mL bottle.
- Alcohol prep pads and a sharps container.
Record keeping
Log the date, units drawn, and site for every injection, alongside any symptoms. This catches gradual dose drift, and if something does go wrong it identifies exactly which step it started on.